Conservative Surgery, External Radiotherapy, and HDR Brachytherapy in a Single Fraction of 7 Gy in Early Breast Cancer: Long-term Toxicity and Esthetic Assessment

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2012 Sep 15

PMID 22975899

Citations 2

Authors

Aurora Rodriguez Perez

Maria Concepcion Lopez Carrizosa

Pilar Maria Samper Ots

Jose Fermin Perez-Regadera Gomez

Jose Zapatero Ortuno

Juan de Dios Saez Garrido

Manuel Joaquin Martin de Miguel

Affiliations

Soon will be listed here.

Abstract

Introduction: The essential issue in conservative treatment is the quality in breast preservation. When risk factors for local relapse exist, a tumour bed boost is required, but the boost choice remains controversial. Prospectively, we studied long-term toxicity, cosmetic outcome and prognostic factors.

Materials And Methods: After conservative treatment, 115 patients received a single dose of 7 Gy HDR-brachytherapy (HDR-BT) boost between June 1996 and December 2005. Late toxicity was assessed using the LENT-SOMA scale. For esthetic assessment, a subjective scale was used for patients and a modified Fehlauer scale for physicians. Mean age was 56.6 years. Invasive ductal carcinoma (78 %) and lumpectomy (60 %) were predominantly reported. 48 % received chemotherapy (CT).

Results: Regarding toxicity, 39 % of patients reported breast pain, 75 % fibrosis, 56 % telangiectasias, 19 % lymphoedema, and 51 % retraction/atrophy. Concerning management, 22 % of patients with pain and 45 % with lymphoedema were treated. The esthetic result was found satisfactory by 96 % of the patients and 85 % of the physicians. Fibrosis was influenced by CT and a larger irradiated volume and telangiectasias by a greater implant volume.

Conclusions: HDR-BT boost shows good cosmetic effects with acceptable toxicity. Patients overestimate the esthetic outcome. LENT/SOMA is useful to assess chronic toxicity.

Citing Articles

Predictors of poor cosmesis in breast cancer patients treated with adjuvant whole breast radiation therapy plus high-dose-rate interstitial brachytherapy boost after breast conservation surgery.

Feizi N, Arvandi S, Feli M, Mohammadian F, Zahiri Z, Shamsi A J Contemp Brachytherapy. 2022; 14(5):429-437.

PMID: 36478696 PMC: 9720695. DOI: 10.5114/jcb.2022.121403.

The effect of hyperbaric oxygen treatment on late radiation tissue injury after breast cancer: A case-series of 67 patients.

Spruijt N, van den Berg R Diving Hyperb Med. 2020; 50(3).

PMID: 32957121 PMC: 7819722. DOI: 10.28920/dhm50.3.206-213.

References

De La Rochefordiere A, Abner A, Silver B, Vicini F, Recht A, Harris J . Are cosmetic results following conservative surgery and radiation therapy for early breast cancer dependent on technique?. Int J Radiat Oncol Biol Phys. 1992; 23(5):925-31. DOI: 10.1016/0360-3016(92)90896-p. View

Guinot J, Tortajada M, Carrascosa M, Crispin V, Otero A, Rios B . Ten-year results of a phase II study with a single fraction of high-dose-rate brachytherapy (FAST-boost) after whole breast irradiation in invasive breast carcinoma. Clin Transl Oncol. 2012; 14(2):109-15. DOI: 10.1007/s12094-012-0769-3. View

Beadle G, Silver B, Botnick L, Hellman S, Harris J . Cosmetic results following primary radiation therapy for early breast cancer. Cancer. 1984; 54(12):2911-8. DOI: 10.1002/1097-0142(19841215)54:12<2911::aid-cncr2820541216>3.0.co;2-v. View

Hammer J, Seewald D, Track C, Zoidl J, Labeck W . Breast cancer: primary treatment with external-beam radiation therapy and high-dose-rate iridium implantation. Radiology. 1994; 193(2):573-7. DOI: 10.1148/radiology.193.2.7972782. View

Ulutin H, Ash D, Dodwell D . Brachytherapy boost to the tumour bed in high risk patients after limited surgery for breast cancer. Clin Oncol (R Coll Radiol). 2003; 15(3):156-9. DOI: 10.1053/clon.2002.0187. View

Clarke D, Le M, Sarrazin D, Lacombe M, Fontaine F, Travagli J . Analysis of local-regional relapses in patients with early breast cancers treated by excision and radiotherapy: experience of the Institut Gustave-Roussy. Int J Radiat Oncol Biol Phys. 1985; 11(1):137-45. DOI: 10.1016/0360-3016(85)90372-4. View

Manning M, Arthur D, Schmidt-Ullrich R, Arnfield M, Amir C, Zwicker R . Interstitial high-dose-rate brachytherapy boost: the feasibility and cosmetic outcome of a fractionated outpatient delivery scheme. Int J Radiat Oncol Biol Phys. 2000; 48(5):1301-6. DOI: 10.1016/s0360-3016(00)00792-6. View

Romestaing P, Lehingue Y, Carrie C, Coquard R, Montbarbon X, Ardiet J . Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol. 1997; 15(3):963-8. DOI: 10.1200/JCO.1997.15.3.963. View

Arenas M, Sabater S, Hernandez V, Henriquez I, Ameijide A, Anglada L . Cosmetic outcome of breast conservative treatment for early stage breast cancer. Clin Transl Oncol. 2006; 8(5):334-8. DOI: 10.1007/s12094-006-0179-5. View

10.

Resch A, Potter R, Van Limbergen E, Biber E, Klein T, Fellner C . Long-term results (10 years) of intensive breast conserving therapy including a high-dose and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer. Radiother Oncol. 2002; 63(1):47-58. DOI: 10.1016/s0167-8140(02)00022-1. View

11.

Harris J, LEVENE M, Svensson G, Hellman S . Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1979; 5(2):257-61. DOI: 10.1016/0360-3016(79)90729-6. View

12.

Wazer D, DiPetrillo T, Schmidt-Ullrich R, Weld L, Smith T, MARCHANT D . Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol. 1992; 10(3):356-63. DOI: 10.1200/JCO.1992.10.3.356. View

13.

Toledano A, Bollet M, Fourquet A, Azria D, Gligorov J, Garaud P . Does concurrent radiochemotherapy affect cosmetic results in the adjuvant setting after breast-conserving surgery? Results of the ARCOSEIN multicenter, Phase III study: patients' and doctors' views. Int J Radiat Oncol Biol Phys. 2007; 68(1):66-72. DOI: 10.1016/j.ijrobp.2006.12.006. View

14.

Fehlauer F, Tribius S, Holler U, Rades D, Kuhlmey A, Bajrovic A . Long-term radiation sequelae after breast-conserving therapy in women with early-stage breast cancer: an observational study using the LENT-SOMA scoring system. Int J Radiat Oncol Biol Phys. 2003; 55(3):651-8. DOI: 10.1016/s0360-3016(02)04120-2. View

15.

Rose M, Olivotto I, Cady B, Koufman C, Osteen R, Silver B . Conservative surgery and radiation therapy for early breast cancer. Long-term cosmetic results. Arch Surg. 1989; 124(2):153-7. DOI: 10.1001/archsurg.1989.01410020023002. View

16.

Van Limbergen E, Rijnders A, van der Schueren E, Lerut T, Christiaens R . Cosmetic evaluation of breast conserving treatment for mammary cancer. 2. A quantitative analysis of the influence of radiation dose, fractionation schedules and surgical treatment techniques on cosmetic results. Radiother Oncol. 1989; 16(4):253-67. DOI: 10.1016/0167-8140(89)90037-6. View

17.

Olivotto I, Rose M, OSTEEN R, Love S, Cady B, Silver B . Late cosmetic outcome after conservative surgery and radiotherapy: analysis of causes of cosmetic failure. Int J Radiat Oncol Biol Phys. 1989; 17(4):747-53. DOI: 10.1016/0360-3016(89)90061-8. View

18.

Polgar C, Fodor J, Orosz Z, Major T, Takacsi-Nagy Z, Mangel L . Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer first results of the randomized Budapest boost trial. Strahlenther Onkol. 2002; 178(11):615-23. DOI: 10.1007/s00066-002-1053-1. View

19.

Budrukkar A, Sarin R, Shrivastava S, Deshpande D, Dinshaw K . Cosmesis, late sequelae and local control after breast-conserving therapy: influence of type of tumour bed boost and adjuvant chemotherapy. Clin Oncol (R Coll Radiol). 2007; 19(8):596-603. DOI: 10.1016/j.clon.2007.06.008. View

20.

Hoeller U, Kuhlmey A, Bajrovic A, Grader K, Berger J, Tribius S . Cosmesis from the patient's and the doctor's view. Int J Radiat Oncol Biol Phys. 2003; 57(2):345-54. DOI: 10.1016/s0360-3016(03)00589-3. View